Today: 20 May 2026
UAMY stock jumps nearly 10% in premarket as antimony prices firm and China supply data hits tape
26 January 2026
2 mins read

UAMY stock jumps nearly 10% in premarket as antimony prices firm and China supply data hits tape

New York, Jan 26, 2026, 05:21 (EST) — Premarket

  • Shares of United States Antimony jumped nearly 10% in premarket trading following Friday’s close.
  • Antimony price benchmarks edged up during the session, fueling renewed interest in critical-minerals stocks.
  • Investors are eyeing follow-through after the open, with the next earnings date set for early April.

Shares of United States Antimony Corporation jumped roughly 10% in Monday’s premarket, pushing the NYSE American-listed UAMY to about $11.93, according to data from Public.com. Pre-market volume hit close to 218,000 shares.

Antimony prices climbed in the latest daily assessments. On Jan. 26, SMM’s benchmark for 1# antimony ingot rose roughly $270 to an average of $20,685.73 per metric ton. Meanwhile, the U.S. in-warehouse antimony price indicator (99.65% Sb min) held steady at $18.25 a pound.

Overnight, traders digested fresh supply data out of China. According to SMM, customs figures showed December 2025 imports of “other antimony ores and concentrates” climbed to 4,775.96 metric tons, up from 3,637.04 tons in November. Market watchers now anticipate a “significant” rebound in antimony prices from recent lows. Metal News

In another update, SMM reported that China’s antimony oxide exports jumped to 382.25 tons in December 2025, a 26.57% increase from November’s 302 tons, following several months of sluggish shipments. The group noted that a wider rebound in exports could boost confidence in antimony prices throughout 2026.

Company-specific action has slowed since last week, but investors remain focused on U.S. Antimony’s recent move to boost processing capacity. On Jan. 20, the company announced it finalized the purchase of a critical minerals flotation facility in Radersburg, Montana, for $4.75 million in cash. It also earmarked roughly $2 million for equipment upgrades. The facility is located less than 250 miles from its Thompson Falls smelter, where an expansion is reportedly “on track” for completion and commissioning by February. Nasdaq

A flotation mill employs chemicals and air bubbles to separate minerals from crushed ore—a crucial step miners take to concentrate feed before smelting. Chairman and CEO Gary C. Evans emphasized the company needs this facility “to properly concentrate the material” and produce “mil-spec” antimony trisulfide, which is reportedly used as a primer in ammunition. Nasdaq

U.S. Antimony’s latest SEC filing on its website is a Form 8-K dated Jan. 20. No updates appeared over the weekend.

Supply politics continue to weigh on investors beyond company news. China lifted its ban on exports of gallium, germanium, and antimony to the U.S. until Nov. 27, 2026, Reuters reported in November. However, these metals remain subject to wider export controls requiring licenses.

The metal market hasn’t followed a simple path. Fastmarkets reported that antimony prices surged to a record $59,750 per tonne in July 2025, then dropped as new smelters ramped up output and the steep costs curbed demand. This highlights how shifts in supply and substitution can quickly change the trade.

Investors will be watching closely after the bell to see if Monday’s early gains stick during regular hours and if antimony prices continue their strength following fresh China trade figures. U.S. Antimony is scheduled to report earnings next on April 6, per Investing.com.

Stock Market Today

  • Roivant Sciences Q4 Loss Beats Estimates; Revenue Misses
    May 20, 2026, 9:59 AM EDT. Roivant Sciences Ltd. reported a fourth-quarter loss of $0.23 per share, better than the Zacks estimate of a $0.25 loss, marking an 8% positive earnings surprise. Revenue missed expectations, coming in at $28.93 million, down 11% from estimates but up from $27.38 million a year ago. Despite three out of four quarters beating EPS estimates recently, the company's shares have declined 4.5% year-to-date, underperforming the S&P 500's 10.4% rise. Earnings outlook remains cautious with a Zacks Rank #4 (Sell), suggesting expected near-term underperformance. Current consensus projects a loss of $0.21 per share next quarter on $56.64 million revenue and a fiscal year loss of $1.07 on $172.45 million. Industry outlook in medical-biomedical genetics also weighs on investor sentiment.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Lloyds Banking Group share price lifts as profit-target talk grows ahead of results
Previous Story

Lloyds Banking Group share price lifts as profit-target talk grows ahead of results

Freeport-McMoRan stock pops in premarket as gold rips past $5,100 and copper stays hot
Next Story

Freeport-McMoRan stock pops in premarket as gold rips past $5,100 and copper stays hot

Go toTop